-
Most Popular
ARNA
Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?
Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena's numbers. They might be pleasantly surprised.
3 High-Flying ETFs That Still Look Good
These three are among the best-performing funds so far this year and, comparatively speaking, look to hold their own at least in the short term.
Will Vivus Repeat Arena’s Non-Response?
Two days don't make or break a stock, but Vivus' response to Qsymia's approval is far from encouraging. The time to buy might be long past.
7 Long-Term Demographic Trends to Play
Earnings and stock fundamentals are important, but don't miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your eye on.
FDA Approves Second Diet Drug in 2 Months
The U.S. Food & Drug Administration has already approved two weight loss drugs this year. The drug Qsymia, made by Vivus, was approved today.
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.
Investors Bag the Groceries: Thursday’s IP Market Recap
Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower.
Should I Buy Weight Watchers? 3 Pros, 3 Cons
Weight Watchers has many things going for it and could get a lift from Obamacare -- but is it a good buy? Here's the verdict.
Court Speaks, Markets Listen — Thursday’s IP Market Recap
The Supreme Court ruling in favor of Obama's Affordable Care Act hit markets initially, but the indices managed to cut most losses by the end of the day.
Bernanke’s Markets Twist Again: Wednesday’s IP Market Recap
The Fed Open Market Committee opted to extend Operation Twist, and the stock markets reacted with a bit of a shrug, finishing mixed on the day.
5 of Pharma’s Most Disastrous Drug Approvals
These five exciting drug approvals now serve as warning stories about the potential pitfalls for investors trying to time a pharma stock buy.
